Triptolide prevents bone loss by inhibiting osteoclastogenesis&nbsp;

doi:10.13418/j.issn.1001-165x.2023.1.14

PDF(3017 KB)

Chinese Journal of Clinical Anatomy ›› 2023, Vol. 41 ›› Issue (1) : 77-80. DOI: 10.13418/j.issn.1001-165x.2023.1.14

Triptolide prevents bone loss by inhibiting osteoclastogenesis

Chen Junze¹, Yu Hui², Xiao Jin²*

Author information +

History +

Abstract

Objective To investigate the antiosteoporotic effect and mechanism of triptolide. Methods A rat model of senile osteoporosis was established. Forty 22-month-old male SD rats were randomly divided into a treatment group of triptolide (15 μg/kg per day intraperitoneally) and a control group of saline (15 μg/kg per day intraperitoneally) for 8 weeks treatment. Bone mineral density (BMD) and bone microstructure of the proximal tibial cancellous were analyzed by micro-CT. Western blot was used to detect the expression level of osteogenic-related proteins. The number of osteoclasts was measured by TRACP-5b staining, and the expression levels of bone resorption markers were also detected. Results Micro-CT results showed that BMD, bone volume/total volume ratio (Bv/Tv), bone trabecular thickness (Tb.Th), bone trabecular number (Tb.N), and bone trabecular spacing (Tb.Sp) in the rats treated with ryanodine were significantly higher than those in the control group (P<0.05). There was no significant difference in osteogenesis-related protein expression between the two groups, and TRACP staining result showed that triptolide reduced the number of osteoclasts in vivo (P<0.05), while blood bone resorption marker levels were also significantly lower (P<0.05). Conclusions Triptolide has a protective effect on age-related osteoporosis by inhibiting osteoclastogenesis. Which may be a feasible option for the treatment of senile osteoporosis.

Key words

Triptolide; / / Osteoporosis; / / Osteoblast; / / Osteoclast

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Chen Junze, Yu Hui, Xiao Jin. Triptolide prevents bone loss by inhibiting osteoclastogenesis [J]. Chinese Journal of Clinical Anatomy. 2023, 41(1): 77-80 https://doi.org/10.13418/j.issn.1001-165x.2023.1.14

References

[1] Rubin CD. Age-related osteoporosis[J]. Am J Med Sci, 1991,301(4):281-298. DOI: 10.1097/00000441-199104000-00012.
[2] Heaney RP. Age-related osteoporosis in Chinese women[J]. Am J Clin Nutr, 1999,69(6):1291-1292. DOI: 10.1093/ajcn.
[3] Maclaughlin EJ, Sleeper RB, McNatty D, et al. Management of age-related osteoporosis and prevention of associated fractures[J]. Ther Clin Risk Manag, 2006,2(3):281-295. DOI: 10.2147/tcrm.2006.2.3.281.
[4] 丁超. 老年性骨质疏松症相关问题研究进展[J]. 中国骨质疏松杂志, 2016,22(3):372-375. DOI：10.3969/j.issn.1006-7108.2016.03.025.
[5] Compston JE, McClung MR, Leslie WD. Osteoporosis[J]. Lancet, 2019,393(10169):364-376. DOI: 10.1016/S0140-6736(18)32112-3.
[6] Wang Y, Wang B, Yang X. The Study of Cellular Mechanism of Triptolide in the Treatment of Cancer, Bone Loss and Cardiovascular Disease and Triptolide's Toxicity[J]. Curr Stem Cell Res Ther, 2020,15(1):18-23. DOI: 10.2174/1574888X14666190301155810.
[7] Park B. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells[J]. Biochimie, 2014,105:129-136. DOI: 10.1016/j.biochi.2014.07.003.
[8] Cui J, Li X, Wang S, et al. Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway[J]. J Cell Mol Med, 2020,24(11):6149-6161. DOI: 10.1111/jcmm.15229.
[9] 彭坤. 骨质疏松性骨折治疗效果的改善：研究现状及策略分析[J]. 中国组织工程研究, 2022, 26(6):1027-1032. DOI: 10.12307/2022.189.
[10]张文静. 骨质疏松治疗的相关研究进展[J]. 中国老年保健医学, 2020,18(04):101-102. DOI: 10.3969/j.issn.1672-2671.2020.04.033.
[11]井莹莹, 王一力, 苏佳灿. 骨微环境对骨质疏松性骨折骨愈合的作用及其机制[J]. 中华创伤杂志, 2021, 37(8):683-687. DOI: 10.3760/cma.j.cn501098-20210331-00215.
[12]邓飞飞, 宋强, 张成涛, 等. 骨质疏松相关分子病因及治疗研究进展[J]. 中华实验外科杂志, 2021,38(6):1186-1188. DOI: 10.3760/cma.j.cn421213-20201023-01379.
[13]林若慧, 李生强, 陈娟, 等. 长链非编码RNA的中医药治疗骨质疏松症研究进展[J]. 中国骨质疏松杂志, 2021,27(9):1395-1399. DOI: 10.3969/j.issn.1006-7108.2021.09.029.
[14]Ogbechi J, Clanchy FI, Huang YS, et al. IDO activation, inflammation and musculoskeletal disease[J]. Exp Gerontol, 2020,131:110820. DOI: 10.1016/j.exger.2019.110820.
[15]Lacativa PG, Farias ML. Osteoporosis and inflammation[J]. Arq Bras Endocrinol Metabol, 2010,54(2):123-132. DOI: 10.1590/s0004-27302010000200007.
[16] Fang H, Zhang H, Wang Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture[J]. J Clin Lab Anal, 2020,34(1):e23016. DOI: 10.1002/jcla.23016.
[17] 李晶芳, 韩蕊, 殷宏庆, 等. 雷公藤治疗肾脏疾病及其毒副作用的研究进展[J]. 中国实验方剂学杂志, 网络首发时间：2021-05-20. DOI: 10.13422/j.cnki.syfjx.20211305.
[18] Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours[J]. Eur J Cancer, 2009,45(10):1764-1772. DOI: 10.1016/j.ejca.2009.01.026.
[19] Yuan Z, Zhang H, Hasnat M, et al. A new perspective of triptolide-associated hepatotoxicity: Liver hypersensitivity upon LPS stimulation[J]. Toxicology, 2019,414:45-56. DOI: 10.1016/j.tox.2019.01.005.